NOVEL α-GALACTOSYLCERAMIDE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION FOR THE IMMUNE ADJUVANT CONTAINING THE SAME AS AN ACTIVE INGREDIENT
PURPOSE: A pharmaceutical composition containing alpha-galactosylceramide derivativews and pharmaceutically acceptable salt thereof is provided to ensure excellent stability and solubility. CONSTITUTION: An alpha-galactosylceramide derivative is denoted by chemical formula 1. In chemical formula 1, n is 5-15 and X or Y is 0-13 integer. A pharmaceutical composition for immunoadjuvant contains the novel alpha-galactosylceramide derivative or pharmaceutically acceptable salt thereof as an active ingredient. The pharmaceutical composition is singly administered or administered by loading to dendritic cells or B cells. An oral or mucosal vaccine contains the pharmaceutical composition..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Europäisches Patentamt - (2018) vom: 27. Sept. Zur Gesamtaufnahme - year:2018 |
|---|
| Sprache: |
Unbestimmt |
|---|
| Beteiligte Personen: |
KIM SANG HEE [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), Last update posted on www.epo.org: 2018-09-27, Last updated: 2021-03-11 |
|---|
| Patentnummer: |
KR20120037920 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA006200559 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA006200559 | ||
| 003 | DE-627 | ||
| 005 | 20230503183137.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210531s2018 xx |||||o 00| ||und c | ||
| 035 | |a (DE-627)EPA006200559 | ||
| 035 | |a (EPA)KR20120037920 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a und | ||
| 100 | 0 | |a KIM SANG HEE |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a NOVEL α-GALACTOSYLCERAMIDE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION FOR THE IMMUNE ADJUVANT CONTAINING THE SAME AS AN ACTIVE INGREDIENT |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), Last update posted on www.epo.org: 2018-09-27, Last updated: 2021-03-11 | ||
| 520 | |a PURPOSE: A pharmaceutical composition containing alpha-galactosylceramide derivativews and pharmaceutically acceptable salt thereof is provided to ensure excellent stability and solubility. CONSTITUTION: An alpha-galactosylceramide derivative is denoted by chemical formula 1. In chemical formula 1, n is 5-15 and X or Y is 0-13 integer. A pharmaceutical composition for immunoadjuvant contains the novel alpha-galactosylceramide derivative or pharmaceutically acceptable salt thereof as an active ingredient. The pharmaceutical composition is singly administered or administered by loading to dendritic cells or B cells. An oral or mucosal vaccine contains the pharmaceutical composition. | ||
| 650 | 4 | |a C07H | |
| 650 | 4 | |a A61K | |
| 650 | 4 | |a che | |
| 650 | 4 | |a A61P | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a KANG CHANG YUIL |e verfasserin |4 aut | |
| 700 | 0 | |a BAEK DONG JAE |e verfasserin |4 aut | |
| 700 | 0 | |a LEE DOO HYUN |e verfasserin |4 aut | |
| 700 | 0 | |a LEE YOON SOOK |e verfasserin |4 aut | |
| 700 | 0 | |a KANG MIN HEE |e verfasserin |4 aut | |
| 700 | 0 | |a LEE JAE YOUNG |e verfasserin |4 aut | |
| 700 | 0 | |a LEE KYOO A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2018) vom: 27. Sept. |
| 773 | 1 | 8 | |g year:2018 |g day:27 |g month:09 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/searchResults?DB=EPODOC&locale=en_EP&query=KR20120037920A |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | u | w | |j 2018 |b 27 |c 09 |
| 951 | |a AR | ||
| 952 | |j 2018 |b 27 |c 09 | ||